Despite these challenges towards defining the scope of PRC2/HDAC interaction specific to MM, accumulating evidence suggests a generalized effect including downregulation of oncogenic pathways and upregulation of tumor suppressors. The gene discussed is HDAC9; the disease is Miyoshi myopathy.